. Author manuscript; available in PMC: 2018 Jan 1.

Published in final edited form as: Clin Pharmacokinet. 2017 Jan;56(1):25–40. doi: 10.1007/s40262-016-0424-1

Table 4.

Pharmacodynamic Characteristics of Integrase Strand Transfer Inhibitors

	Dolutegravir	Elvitegravir	Raltegravir
IC₅₀ (ng/mL) IC₉₀ (ng/mL) IC₉₅ (ng/mL)	16 64 na	7.2 na 44.9	na na 14.7
EC₅₀ (ng/mL) EC₉₀ (ng/mL)	36 324	14 126	na na
IQ (C_trough / IC_{90 or 95})	17	10	8

Abbreviations: C_trough, measured concentration at the end of the dosing interval; IC, protein-binding adjusted concentration inhibiting viral replication by 50, 90 or 95% in vitro; EC, concentration producing 50 or 90% effect (reduction of HIV-RNA) in vivo; IQ, inhibitory quotient; na, not available.